IDO2 and medullary thyroid gland carcinoma: Next, due to the relatively good prognosis of MTC, only 22 (11.8%) recurrences and 13 (6.9%) disease-related deaths have been observed; thus, the effect of IDO2 on prognosis may not be fully assessed.